-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PNbRNJC8Csd0ET3Eiic6bFSOG2Vy3gH9kQwRrh8L/8sTEH328PqyLBipfwqTmUhT 8GvRQLEZkt2VfzG6MgdFhA== 0000950133-02-003810.txt : 20021118 0000950133-02-003810.hdr.sgml : 20021118 20021114173738 ACCESSION NUMBER: 0000950133-02-003810 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020930 FILED AS OF DATE: 20021114 EFFECTIVENESS DATE: 20021115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 02826586 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 w65800e13fvhr.txt FORM 13F-HR FOR BB BIOTECH AG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: September 30, 2002 Check here if Amendment [ ]; Amendment Number: This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Adrian Brungger Title: SIGNING AUTHORITY ---------------- Phone: (41-41) 724-5959 Signature, Place, and Date of Signing: /s/ ADRIAN BRUNGGER ---------------------------------------- Zug, Switzerland, November 14, 2002 Report Type (Check only one.): [ ] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [X] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: Name Biotech Focus N.V. Biotech Invest N.V. Biotech Target N.V. Biotech Growth N.V. Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 4 Form 13F Information Table Entry Total: 21 Form 13F Information Table Value Total: $881,267 (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Name 1 Biotech Focus N.V. 2 Biotech Invest N.V. 3 Biotech Target N.V. 4 Biotech Growth N.V. BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 -------- -------- -------- -------- -------- -------- -------- -------- TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Adolor Corp. COM 00724X102 24,430 1,742,500 SH DEFINED 3 1,742,500 NONE NONE Amgen Inc. COM 00075886F1 251,660 6,035,000 SH DEFINED 1 6,035,000 NONE NONE CV Therapeutics, Inc. COM 12666710 38,958 1,863,147 SH DEFINED 3 1,863,147 NONE NONE Cell Therapeutics, Inc. COM 150934107 4,050 920,500 SH DEFINED 3 920,500 NONE NONE Cephalon Inc. COM 156708109 10,687 261,800 SH DEFINED 1 261,800 NONE NONE Cubist Pharmaceuticals, Inc. COM 229678107 5,723 1,120,000 SH DEFINED 3 1,120,000 NONE NONE Durect Corporation COM 266605104 6,990 2,254,957 SH DEFINED 3 2,254,957 NONE NONE Endo Pharmaceuticals COM 29264P104 9,272 1,087,000 SH DEFINED 3 1,087,000 NONE NONE Enzon COM 293904108 6,205 322,500 SH DEFINED 3 322,500 NONE NONE Genentech COM 812578102 32,630 1,000,000 SH DEFINED 1 1,000,000 NONE NONE IDEC Pharmaceuticals COM 449370105 211,752 5,100,000 SH DEFINED 1 5,100,000 NONE NONE IDEC Pharmaceuticals LYON 449370AD7 23,849 42,000,000 PRN DEFINED 3 42,000,000 NONE NONE ZERO CPN Medicines Company (The) COM 584688105 34,970 3,185,500 SH DEFINED 3 3,185,500 NONE NONE MedImmune COM 584699102 84,621 4,045,000 SH DEFINED 1 4,045,000 NONE NONE Neurocrine Biosciences COM 64125C109 76,703 1,870,800 SH DEFINED 3 1,870,800 NONE NONE Pozen, Inc. COM 73941U102 14,196 2,800,000 SH DEFINED 3 2,800,000 NONE NONE Regeneron COM 75886F107 3,240 240,000 SH DEFINED 3 240,000 NONE NONE Pharmaceuticals, Inc. Serono SA ADR 81752M101 6,035 500,000 SH DEFINED 1 500,000 NONE NONE 3-Dimensional COM 88554W104 8,466 2,850,483 SH DEFINED 3 2,850,483 NONE NONE Pharmaceuticals, Inc. Transkaryotic Therapies COM 89373510 22,684 699,900 SH DEFINED 2 699,900 NONE NONE Virologic COM 92823R201 4,146 3,605,004 SH DEFINED 3 3,605,004 NONE NONE
-----END PRIVACY-ENHANCED MESSAGE-----